Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
A research project is currently being undertaken looking at Human Papilloma Virus (HPV)
vaccination in special risk groups. It aims to see if young women with a chronic illness
respond well to the HPV vaccine or whether they may require additional doses to ensure
protective immunity. The four valent HPV vaccine protects against HPV types 16 & 18, cervical
cancer and HPV types 6 & 11, anogenital warts.
The six special risk groups include:
Paediatric Rheumatological Disease Inflammatory Bowel Disease Acute Lymphoblastic Leukaemia
Solid Organ Transplant Recipients (kidney and liver) Chronic Renal Disease Bone Marrow
Transplants This immunity is measured by antibody levels of the HPV types, which requires a
single blood test one month after the final dose of HPV vaccine.
This is compared to healthy controls using antibody response to HPV vaccine. This will assess
directly whether these special risk groups respond as well to the HPV vaccine.
Phase:
Phase 3
Details
Lead Sponsor:
Murdoch Childrens Research Institute
Collaborators:
Brockhoff Foundation Australia Shepherd Foundation Australia